APAC Sickle Cell Disease Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$688.0 MnPlaceholder estimate
Estimate 2025$820.8 Mn21.1% of the global market
Projected 2034$4.02 Bn 389.5%Adds $3.20 Bn over 9 forecast years
CAGR 2025–203419.3%Faster than 83% of 180 Pharmaceuticals markets here
Key players5
APAC is 21.05% of the global market.
Among regions, the largest is North America at $2.17 Bn.
Fastest growing: APAC (this report) at 19.3% a year.
APAC ranks 2nd of 6 by size among regions.
Market size projection
APAC
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$3.20 Bn total, 2026–2034
Year-by-year market size, 2024–2034
Sickle Cell Disease Therapeutics Market market size by year, APAC
Year
Market size
Change that year
Since 2025
2024 (estimate)
$688.0 Mn
—
—
2025 (base)
$820.8 Mn
+$132.8 Mn
—
2026 (forecast)
$979.2 Mn
+$158.4 Mn
+19.3%
2027 (forecast)
$1.17 Bn
+$189.0 Mn
+42.3%
2028 (forecast)
$1.39 Bn
+$225.5 Mn
+69.8%
2029 (forecast)
$1.66 Bn
+$269.0 Mn
+102.6%
2030 (forecast)
$1.98 Bn
+$320.9 Mn
+141.7%
2031 (forecast)
$2.37 Bn
+$382.8 Mn
+188.3%
2032 (forecast)
$2.82 Bn
+$456.7 Mn
+243.9%
2033 (forecast)
$3.37 Bn
+$544.8 Mn
+310.3%
2034 (forecast)
$4.02 Bn
+$650.0 Mn
+389.5%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Vertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG, Novo Nordisk A/S (see all)
Active clinical trials
11 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Sickle Cell Disease Therapeutics Market Analysis Executive Summary
Sickle cell disease therapeutics include gene therapies, gene editing and medicines that reduce pain crises and organ damage.
Key segments of the sickle Cell Disease Therapeutics market include treatment (Gene Therapy, Gene Editing and Hydroxyurea) and age (Pediatric and Adult).
Asia Pacific Sickle Cell Disease Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the sickle Cell Disease Therapeutics market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the sickle Cell Disease Therapeutics market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Sickle Cell Disease Therapeutics Market in APAC
The sickle Cell Disease Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Sickle Cell Disease Therapeutics Market in APAC
Sickle Cell Disease Therapeutics in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 11 studies on Sickle Cell Disease Therapeutics that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sickle Cell Disease Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Vertex Pharmaceuticals
7.2 bluebird bio
7.3 Pfizer
7.4 Novartis
7.5 Novo Nordisk
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The sickle Cell Disease Therapeutics market can be segmented based on various criteria, including treatment, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Sickle Cell Disease Therapeutics right now, from free public sources.
Clinical trials
11 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Sickle Cell Disease Therapeutics market in Asia Pacific?
Placeholder estimate: about $820.8 Mn in 2025, rising to about $4.02 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sickle Cell Disease Therapeutics market in Asia Pacific growing?
Placeholder estimate: about 19.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sickle Cell Disease Therapeutics market report cover?
The report splits the market by treatment (Gene Therapy, Gene Editing, Hydroxyurea, Disease-Modifying Drugs), age (Pediatric, Adult) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Sickle Cell Disease Therapeutics market?
Key players include Vertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG and Novo Nordisk A/S.
What is driving the Sickle Cell Disease Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.
How many clinical trials on Sickle Cell Disease Therapeutics are running in Asia Pacific?
11 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Sickle Cell Disease Therapeutics?
PubMed lists 3,466 papers on Sickle Cell Disease Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
France
UK
Italy
Brazil
Spain
Ecuador
India
Saudi Arabia
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
Sanofi